Structural and temporal dynamics of nano-based therapies in ulcerative colitis: history, hotspots, and emerging
Junzu Shi1, Danyang Cui1, Li Yu1
1Department of Traditional Chinese Medicine, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
Background:
Nanomaterial-based therapies have emerged as a promising approach for ulcerative colitis (UC). To systematically map the field, we performed a bibliometric analysis of research over the past 25 years, aiming to reveal knowledge evolution, core themes, and emerging trends.
Methods:
We searched the Web of Science Core Collection and Scopus for English-language publications (2001-2025) using the keywords "nanomaterials" and "ulcerative colitis" including original articles and reviews. After deduplication, 1,316 publications were analyzed using CiteSpace, HistCite, and R to construct collaboration networks, keyword co-occurrence maps, co-citation networks, and thematic evolution analyses.
Results:
UC-focused nanotherapeutics show sustained growth and increasing international collaboration, with China as the leading contributor. Analysis identified 57 subject categories, 537 keywords, and 899 publications with citation bursts. Five emerging themes were highlighted: gut microbiota, reactive oxygen species, NLRP3 inflammasome, drug delivery systems, and polymeric nanoparticles. Nanotechnology is increasingly integrated into UC pathogenesis studies, with a shift from passive drug delivery toward intelligent, mechanism-driven, and combination therapies. Co-citation analysis identified seven core areas, including inflammation regulation, targeted delivery, immune modulation, hydrogel carriers, and nanotherapeutics.
Conclusion:
This study maps the evolving landscape of UC nanotherapeutics, highlighting the field's shift toward precise, intelligent, and mechanism-guided strategies. Future research should emphasize nanodesign, safety evaluation, and personalized therapies, facilitating translational innovation.
More Related Videos
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...


